← Leaderboards
Catherine Ju-Ying Wu
Broad Institute, Inc.
$43,266,044
Attributed
$56,210,147
Total exposure
26
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $16.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$73,177,513 · 27
By mechanism
P01$25,196,133 · 11
R01$24,551,849 · 8
U24$16,455,371 · 1
R21$2,287,923 · 4
U54$2,090,715 · 1
P50$1,958,727 · 1
Top collaborators
- Lili Wang5 shared
- Frank S Hodi4 shared
- Fei Chen3 shared
- Vincent Trien-Vinh Ho3 shared
- Derin B Keskin3 shared
- Peter V Kharchenko3 shared
- Shanye Yin2 shared
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingResponseCellsTumorMalignant NeoplasmsChronic Lymphocytic LeukemiaMutationBaseMolecularGenomicsCancer CellImmunotherapyLinkGeneticB-LymphocytesClinical TrialsAntigensProgramsResistanceDissectionT-LymphocyteLeukemiaInsightDetection
Grant awards (113)
Cancer Immune Monitoring and Analysis Center$1,934,873
U24 · FY2025 · CA · contact PI
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes$1,635,928
P01 · FY2025 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$759,203
R01 · FY2025 · CA · contact PI
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment$699,616
R01 · FY2025 · CA
Defining the determinants of response and resistance to therapy for Richter's Syndrome$364,213
P01 · FY2025 · CA · contact PI
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC$214,790
P50 · FY2025 · CA · contact PI
Administrative Core$79,565
P01 · FY2025 · CA · contact PI
Cancer Immune Monitoring and Analysis Center$1,838,130
U24 · FY2024 · CA · contact PI
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes$1,546,492
P01 · FY2024 · CA · contact PI
Systematic identification of minor histocompatibility antigens to address GVHD$723,738
R01 · FY2024 · HL
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$714,052
R01 · FY2024 · CA · contact PI
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment$664,636
R01 · FY2024 · CA
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC$389,502
P50 · FY2024 · CA · contact PI
Defining the determinants of response and resistance to therapy for Richter's Syndrome$354,075
P01 · FY2024 · CA · contact PI
Administrative Core$66,222
P01 · FY2024 · CA · contact PI
Cancer Immune Monitoring and Analysis Center$1,973,873
U24 · FY2023 · CA · contact PI
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes$1,596,896
P01 · FY2023 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$751,633
R01 · FY2023 · CA · contact PI
Systematic identification of minor histocompatibility antigens to address GVHD$738,508
R01 · FY2023 · HL
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment$691,271
R01 · FY2023 · CA
Antigenic basis of immune responses after immune modulatory therapies post-HCT$568,895
P01 · FY2023 · CA · contact PI
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC$389,350
P50 · FY2023 · CA · contact PI
Defining the determinants of response and resistance to therapy for Richter's Syndrome$356,911
P01 · FY2023 · CA · contact PI
Defining the impact of mutational drivers on the immune microenvironment of CLL$203,878
R21 · FY2023 · CA · contact PI
Administrative Core$72,897
P01 · FY2023 · CA · contact PI
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes$1,596,329
P01 · FY2022 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$771,133
R01 · FY2022 · CA · contact PI
Systematic identification of minor histocompatibility antigens to address GVHD$760,557
R01 · FY2022 · HL
Antigenic basis of immune responses after immune modulatory therapies post-HCT$565,188
P01 · FY2022 · CA · contact PI
Defining the determinants of response and resistance to therapy for Richter's Syndrome$356,833
P01 · FY2022 · CA · contact PI
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC$341,960
P50 · FY2022 · CA · contact PI
Defining the impact of mutational drivers on the immune microenvironment of CLL$249,645
R21 · FY2022 · CA · contact PI
Administrative Core$68,351
P01 · FY2022 · CA · contact PI
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes$1,667,862
P01 · FY2021 · CA · contact PI
Antigenic basis of immune responses after immune modulatory therapies post-HCT$576,722
P01 · FY2021 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$538,977
R01 · FY2021 · CA · contact PI
Defining the determinants of response and resistance to therapy for Richter's Syndrome$373,544
P01 · FY2021 · CA · contact PI
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC$284,060
P50 · FY2021 · CA · contact PI
Administrative Core$71,178
P01 · FY2021 · CA · contact PI
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes$1,687,447
P01 · FY2020 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$675,300
R01 · FY2020 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$669,100
R01 · FY2020 · CA · contact PI
Antigenic basis of immune responses after immune modulatory therapies post-HCT$576,722
P01 · FY2020 · CA · contact PI
CLL clonal evolution and the development of therapy-driven resistance$360,802
P01 · FY2020 · CA · contact PI
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC$339,065
P50 · FY2020 · CA · contact PI
Administrative Core$148,245
P01 · FY2020 · CA · contact PI
Program Integration$91,741
P01 · FY2020 · CA · contact PI
Expansion of antigen-specific T cells using programmable biomaterials for adoptive cellular therapy$2,090,715
U54 · FY2019 · CA · contact PI
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes$1,639,141
P01 · FY2019 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$885,964
R01 · FY2019 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$655,040
R01 · FY2019 · CA · contact PI
Antigenic basis of immune responses after immune modulatory therapies post-HCT$576,722
P01 · FY2019 · CA · contact PI
CLL clonal evolution and the development of therapy-driven resistance$353,902
P01 · FY2019 · CA · contact PI
Comprehensive Dissection of the CLL Genome and Phenome to Improve Patient Outcomes$197,757
P01 · FY2019 · CA · contact PI
Integrated genetic and phenotypic analysis of therapeutic resistance in chronic lymphocytic leukemia using functionalized lineage tracing$197,757
P01 · FY2019 · CA · contact PI
Administrative Core$141,343
P01 · FY2019 · CA · contact PI
Single-cell analysis of tumor-microenvironment interactions in follicular lymphoma$132,727
R21 · FY2019 · CA
Program Integration$84,839
P01 · FY2019 · CA · contact PI
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes$1,755,838
P01 · FY2018 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$740,321
R01 · FY2018 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$675,300
R01 · FY2018 · CA · contact PI
CLL clonal evolution and the development of therapy-driven resistance$370,572
P01 · FY2018 · CA · contact PI
Defining the impact of clonal evolution on chronic lymphocytic leukemia$362,378
R01 · FY2018 · CA · contact PI
Administrative Core$158,016
P01 · FY2018 · CA · contact PI
Single-cell analysis of tumor-microenvironment interactions in follicular lymphoma$136,832
R21 · FY2018 · CA
Program Integration$101,509
P01 · FY2018 · CA · contact PI
Cancer Immune Monitoring and Analysis Center$10,708,495
U24 · FY2017 · CA · contact PI
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes$1,755,838
P01 · FY2017 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$701,924
R01 · FY2017 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$675,300
R01 · FY2017 · CA · contact PI
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL$553,684
R01 · FY2017 · CA · contact PI
The role of the SF3B1 splicing factor in chronic lymphocytic leukemia$434,621
R01 · FY2017 · HL · contact PI
CLL clonal evolution and the development of therapy-driven resistance$370,572
P01 · FY2017 · CA · contact PI
Defining the impact of clonal evolution on chronic lymphocytic leukemia$362,378
R01 · FY2017 · CA · contact PI
Administrative Core$158,016
P01 · FY2017 · CA · contact PI
Single-cell analysis of tumor-microenvironment interactions in follicular lymphoma$154,207
R21 · FY2017 · CA
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes$132,000
P01 · FY2017 · CA · contact PI
Program Integration$101,509
P01 · FY2017 · CA · contact PI
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes$1,755,838
P01 · FY2016 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$675,300
R01 · FY2016 · CA · contact PI
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL$553,684
R01 · FY2016 · CA · contact PI
CLL clonal evolution and the development of therapy-driven resistance$463,019
P01 · FY2016 · CA · contact PI
The role of the SF3B1 splicing factor in chronic lymphocytic leukemia$434,621
R01 · FY2016 · HL · contact PI
Defining the impact of clonal evolution on chronic lymphocytic leukemia$362,378
R01 · FY2016 · CA · contact PI
Administrative Core$98,886
P01 · FY2016 · CA · contact PI
Program Integration$1
P01 · FY2016 · CA · contact PI
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL$553,684
R01 · FY2015 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$432,500
R01 · FY2015 · CA · contact PI
The role of the SF3B1 splicing factor in chronic lymphocytic leukemia$428,101
R01 · FY2015 · HL · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$363,125
R01 · FY2015 · CA · contact PI
Defining the impact of clonal evolution on chronic lymphocytic leukemia$362,378
R01 · FY2015 · CA · contact PI
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL$553,684
R01 · FY2014 · CA · contact PI
The role of the SF3B1 splicing factor in chronic lymphocytic leukemia$425,929
R01 · FY2014 · HL · contact PI
Defining the impact of clonal evolution on chronic lymphocytic leukemia$362,378
R01 · FY2014 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$352,231
R01 · FY2014 · CA · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$288,332
R01 · FY2014 · CA · contact PI
The role of the SF3B1 splicing factor in chronic lymphocytic leukemia$413,759
R01 · FY2013 · HL · contact PI
Post-transplant vaccines to enhance graft-versus-leukemia responses$412,335
R01 · FY2013 · HL · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$341,338
R01 · FY2013 · CA · contact PI
Post-transplant vaccines to enhance graft-versus-leukemia responses$433,125
R01 · FY2012 · HL · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$363,125
R01 · FY2012 · CA · contact PI
Post-transplant vaccines to enhance graft-versus-leukemia responses$437,500
R01 · FY2011 · HL · contact PI
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia$363,125
R01 · FY2011 · CA · contact PI
Post-transplant vaccines to enhance graft-versus-leukemia responses$434,583
R01 · FY2010 · HL · contact PI
GM-CSF secreting tumor cell vaccines to enhance post-transplant anti-CLL immunity$378,360
R21 · FY2009 · CA · contact PI
GM-CSF secreting tumor cell vaccines to enhance post-transplant anti-CLL immunity$378,360
R21 · FY2008 · CA · contact PI
GM - CSF - producing tumor cell line as a CML vaccine$323,694
R21 · FY2006 · CA · contact PI
GM-CSF - producing tumor cell line as a CML vaccine$330,220
R21 · FY2005 · CA
LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION$127,359
K08 · FY2004 · HL
LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION$127,359
K08 · FY2003 · HL
LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION$127,359
K08 · FY2002 · HL
LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION$127,359
K08 · FY2001 · HL
LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION$127,359
K08 · FY2000 · HL